- Trials with a EudraCT protocol (76)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
76 result(s) found for: Bristol Stool Scale.
Displaying page 3 of 4.
EudraCT Number: 2009-017874-20 | Sponsor Protocol Number: MA-LA-IBS09-01 | Start Date*: 2010-03-26 | |||||||||||
Sponsor Name:AXCAN PHARMA SAS | |||||||||||||
Full Title: Treatment of Diarrhea-predominant Irritable Bowel Syndrome with LACTEOL 340 mg : a pilot study evaluating safety and efficacy | |||||||||||||
Medical condition: Diarrhea-predominant Irritable Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003690-65 | Sponsor Protocol Number: 78304 | Start Date*: 2021-11-10 |
Sponsor Name:St Antonius Hospital | ||
Full Title: Peppermint Oil for the treatment of Irritable Bowel Syndrome or Functional Abdominal Pain in Children: the MINT study | ||
Medical condition: Irritable Bowel syndrome Functional Abdominal Pain Not otherwise specified | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-003468-30 | Sponsor Protocol Number: SAG/0211PFC-1131 | Start Date*: 2014-09-24 | |||||||||||
Sponsor Name:Sucampo Pharma Europe Ltd. | |||||||||||||
Full Title: A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional... | |||||||||||||
Medical condition: functional constipation in paediatric patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) NL (Completed) PL (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005345-36 | Sponsor Protocol Number: D5610C00001 | Start Date*: 2014-05-13 | |||||||||||
Sponsor Name:Ardelyx, Inc. | |||||||||||||
Full Title: An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabete... | |||||||||||||
Medical condition: Chronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002811-33 | Sponsor Protocol Number: LAINCO1107 | Start Date*: 2017-12-11 | |||||||||||
Sponsor Name:LAINCO S.A | |||||||||||||
Full Title: Unilateral, open and randomized phase IV study of 2 groups to assess the degree of comfort with simple Emuliquen® in patients undergoing proctological surgery | |||||||||||||
Medical condition: Surgery proctological | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002087-10 | Sponsor Protocol Number: 1062.7 | Start Date*: 2007-08-28 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: A randomised, double -blind, placebo-controlled, parallel group study to assess the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops 10 mg administere... | |||||||||||||
Medical condition: To compare the efficacy and safety of 4 weeks treatment with sodium picosulphate [Dulcolax®, Laxoberal®] drops to placebo in patients with functional constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005922-62 | Sponsor Protocol Number: OXN2501 | Start Date*: 2008-05-22 | |||||||||||
Sponsor Name:Mundipharma Research GmbH & Co. KG | |||||||||||||
Full Title: An exploratory, randomised, active-controlled, double-blind, double-dummy, parallel group pilot study to determine the ability of oxycodone/naloxone prolonged release tablets (OXN) to reduce the nu... | |||||||||||||
Medical condition: Opioid induced constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-004155-13 | Sponsor Protocol Number: BMS_IM101-931 | Start Date*: 2023-04-20 | |||||||||||
Sponsor Name:Universitätsklinikum Freiburg | |||||||||||||
Full Title: Study to investigate the restoring of an immunological balance during therapy with abatacept Abatacept restores immune system equilibrium (ARISE) | |||||||||||||
Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003369-85 | Sponsor Protocol Number: ID-069A301 | Start Date*: 2018-05-14 | |||||||||||
Sponsor Name:Idorsia Pharmaceuticals Ltd | |||||||||||||
Full Title: A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease. | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) NL (Completed) BE (Completed) IE (Completed) ES (Ongoing) NO (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000657-39 | Sponsor Protocol Number: 0217/DEV | Start Date*: 2017-08-15 | |||||||||||
Sponsor Name:Develco Pharma Schweiz AG | |||||||||||||
Full Title: Randomised, double-blind, placebo-controlled, parallel-group, multi-centre, phase III trial to investigate the efficacy, safety and tolerability of Naloxone HCl PR Tablets in patients with opioid i... | |||||||||||||
Medical condition: Opioid induced constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) SK (Completed) ES (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004293-26 | Sponsor Protocol Number: QTM/GEP0512 | Start Date*: 2013-09-03 | |||||||||||
Sponsor Name:GeiserPHARMA SL | |||||||||||||
Full Title: Multisite, open, randomized, parallel and controlled clinical trial, to evaluate the efficacy and safety of a laxative fiber formula compared to Plantaben on objective and subjective parameters of ... | |||||||||||||
Medical condition: Occasional constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001678-10 | Sponsor Protocol Number: NL65853.029.18 | Start Date*: 2019-06-06 |
Sponsor Name:VU Medical Center | ||
Full Title: Tofacitinib: salvage therapy for patients with RCDII - a pilot study | ||
Medical condition: Refractory celiac disease type II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000069-34 | Sponsor Protocol Number: PAMORA_2020_RAP | Start Date*: 2021-11-19 | |||||||||||
Sponsor Name:Mech-Sense, Aalborg University Hospital | |||||||||||||
Full Title: Effects of a peripherally acting μ-opioid receptor antagonist on recurrent acute pancreatitis: An investigator-initiated, randomized, placebo-controlled, double-blind clinical trial | |||||||||||||
Medical condition: Recurrent acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004159-56 | Sponsor Protocol Number: MERISUDD | Start Date*: 2017-10-12 | |||||||||||
Sponsor Name:DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: Efficacy and safety of mesalazine, rifaximin, alone or as extemporary combination, in the treatment of symptomatic uncomplicated diverticular disease of colon: multi-centre, randomised, double-blin... | |||||||||||||
Medical condition: Treatment of symptomatic uncomplicated diverticular colon disease (SUDD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003831-31 | Sponsor Protocol Number: MS1819/18/02 | Start Date*: 2019-03-28 | |||||||||||
Sponsor Name:AzurRx | |||||||||||||
Full Title: A multicenter, open-label Phase 2 study with escalating doses of MS1819-SD on top of a stable dose of PPEs, to investigate the efficacy and safety of this combination for the compensation of severe... | |||||||||||||
Medical condition: Exocrine Pancreatic Insufficiency | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) ES (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002414-35 | Sponsor Protocol Number: 3200A3-200-WW | Start Date*: 2006-11-02 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | ||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain. | ||
Medical condition: Opioid induced bowel dysfunction | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) DE (Completed) NL (Completed) DK (Completed) GB (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003647-19 | Sponsor Protocol Number: CELIM-NRCD-001 | Start Date*: 2016-02-22 |
Sponsor Name:Celimmune LLC | ||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Celiac Disease. | ||
Medical condition: Celiac disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000818-29 | Sponsor Protocol Number: MCP-103-403 | Start Date*: 2016-08-08 | |||||||||||
Sponsor Name:Ironwood Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants with Irritable Bowel Syndrom... | |||||||||||||
Medical condition: Irritable Bowel Syndrome with Constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002350-90 | Sponsor Protocol Number: EFC17045 | Start Date*: 2022-04-01 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female participants ≥16 Years of Age with F... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000241-32 | Sponsor Protocol Number: NL80290.018.22 | Start Date*: 2022-08-08 | |||||||||||
Sponsor Name:Amsterdam UMC | |||||||||||||
Full Title: Effectiveness of L-serine dietary supplementation in children with a GRIN2B loss-of-function mutation: n-of-1 series | |||||||||||||
Medical condition: GRIN2B deficiency | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
